Jun 12, 2020
Sun Pharma Announces Long-term Insights into the Clinical Use of ILUMYA(TM) (tildrakizumab-asmn) in a Cross Section of People Living with Moderate-to-Severe Plaque Psoriasis
Jun 11, 2020
Sun Pharma Plans to Present Clinical Insights from 25 Data Abstracts Across its Dermatology Portfolio at the 2020 AAD Virtual Meeting Experience
Apr 20, 2020
HTA in Major Pharma Industries, 2020 - Includes Profiles of Daratumumab (Darzalex), Tildrakizumab (Ilumya), Durvalumab (Imfinzi), Abemaciclib (Verzenio), and Ocrelizumab (Ocrevus)
Oct 09, 2019
Sun Pharma Presents Long-term Study Results that Show Significant Skin Clearance with ILUMYA® (tildrakizumab-asmn) Maintained Over Four Years in People with Moderate-to-Severe Plaque Psoriasis
Jul 25, 2019
Robust Use of Janssen's Tremfya and Positive Early Launch Metrics for AbbVie's Skyrizi May Threaten Growth of IL-17 Inhibitors in US Psoriasis Market, According to Spherix Global Insights
Mar 11, 2019
While Janssen's Tremfya and Sun Pharmaceutical's Ilumya are Enjoying Continued Uptake, AbbVie's Skyrizi (Risankizumab) is Shaping up to be a Major Disruptor to the US Psoriasis Market if Approved
Feb 27, 2019
Sun Pharmaceutical Industries Inc. Announces Plans to Present 19 Data Abstracts on ILUMYA(TM) for Moderate-to-Severe Plaque Psoriasis at American Academy of Dermatology 2019 Annual Meeting
Nov 20, 2018
Spherix Global Insights' Annual Update of the Psoriasis Switching Market Reveals Significant Gains for Janssen's Tremfya, Much to the Detriment of Sister-Brand Stelara
Oct 23, 2018
Sun Pharma Announces the Availability of ILUMYA(TM) (tildrakizumab-asmn) in the United States for the Treatment of Moderate-to-Severe Plaque Psoriasis
Mar 21, 2018
Sun Pharma Announces U.S. FDA Approval of ILUMYA(TM) (tildrakizumab-asmn) for the Treatment of Moderate-to-Severe Plaque Psoriasis
Mar 08, 2018
Next Generation Biologics, Janssen's Tremfya, Eli Lilly's Taltz, and Novartis' Cosentyx, Raising the Bar in Psoriasis Management
Feb 12, 2018
Sun Pharma Announces Twelve Tildrakizumab Abstracts to be Presented at American Academy of Dermatology 2018 Annual Meeting